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prognostic marker in primary lung cancer: association
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Summary The expression of urokinase-type plasminogen activator (u-PA), u-PA receptor (u-PAR) and plasminogen activator inhibitor (PAI)
1 and 2 was examined in 105 cases of primary lung cancer tissue using immunohistochemical staining and reverse transcriptase polymerase
chain reaction (RT-PCR) techniques. The expression of u-PA, u-PAR and PAI-1 was detected in approximately 80% of primary lung cancers,
whereas detectable PAI-2 expression was observed only in half of the overall cases. We assessed the relationships between the expression
pattern and clinicopathological findings and found that a diminished expression level of PAI-2 was significantly correlated with lymph node
metastasis and a poor prognosis. These results indicate that PAI-2 may play a critical role in the regulation of extracellular matrix degradation
during tumour cell invasion and metastasis, and the expression of PAI-2 may be useful as a marker for evaluating the prognosis of lung
cancer.
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It has been established that extracellular matrix proteases, such as
matrix metalloproteinases, serine proteases and cysteine-aspartyl
proteases, play an important role in tumour invasion and meta-
stasis. Urokinase-type plasminogen activator (u-PA), a member of
the serine protease family, converts plasminogen into its activated
form plasmin, which degrades several components of the extracel-
lular matrix and basement membranes (Robbins et al, 1967; Liotta
et al, 1981; Goldfarb et al, 1986). As plasmin itself catalyses the
activation of plasminogen and metalloproteinases, it is assumed to
be a key enzyme in the activation cascade of extracellular matrix
(Salo et al, 1982). After production in tumour cells or surrounding
fibroblasts, u-PA seems to be localized on the cell surface by
binding to a specific receptor (u-PAR), which results in the
focusing ofproteolytic activity around the tumour cells (Blasi et al,
1986). The activity of u-PA is regulated by several plasminogen
activator inhibitors, such as plasminogen activator inhibitor 1 and 2
(PAI-I and PAI-2). We have reported that expression of u-PA, u-
PAR and PAI-I is elevated in malignant tumours and is correlated
with tumour invasiveness and that a low level of PAI-2 expression
is associated with tumour invasion and metastasis (Ishikawa et al,
1996; Noguchi-Takino et al, 1996). In lung cancer, however, there
have been few reports on the significance of u-PA and its related
factors, especially PAI-2. In the current study, we examined expres-
sion of the u-PA series by the reverse transcriptase polymerase
chain reaction (RT-PCR) method and immunohistochemical
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staining, and compared the expression patterns with the clinico-
pathological findings.
MATERIALS AND METHODS
Clinical specimens
Primary lung cancer tissues obtained from 105 patients who
underwent surgery in the Kanazawa University Hospital from
1987 to 1995 were frozen and stored at-80°C. The background of
these patients is presented in Table 1. The 105 tumours included
40 squamous cell carcinomas, 53 adenocarcinomas, six large-cell
carcinomas and six small-cell carcinomas. The pathological stage
was classified as stage I in 55 patients, stage II in three patients
and stage III in 47 patients according to the classification of the
Japan Lung Cancer Society (1995)
Reverse transcription (RT)-PCR
The RT-PCR analysis was performed by a modification of the
method of Conboy et al (1988). Briefly, total RNA was extracted
using Isogen (Nippon Gene, Tokyo, Japan). The prepared RNA
(1 ,ug) was mixed with oligo-dT (50 pmol), incubated for 15 min at
68°C, then quickly chilled in an ice bath for 5 min. RNA samples
were reverse transcribed at 40°C for 90 min into the first-strand
cDNA in reverse transcription (RT) solution [50 mM Tris-HCl
(pH 8.3), 40 mm potassium chloride, 8 mm magnesium chloride,
0.5 mm each dNTPs, 225 .tg ml-' bovine serum albumin, 5 mM
dithiothreitol (DTT), 8 units of RNasin (Promega, Madison, WI,
USA) and 4 units of AMV reverse transcriptase (Life Sciences, St
Petersburg, FL, USA)] with a total volume of 20 tl. The cDNA
samples were incubated at 95°C for 5 min to inactivate the reverse
transcriptase, then chilled. The cDNA samples were amplified in
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Table 1 The basic clinical background of 105 patients with lung cancer
63.8 + 9.2 Mean age (years)
Sex
Male
Female
Histology
Squamous cell carcinoma
Adenocarcinoma
Large-cell carcinoma
Small-cell carcinoma
Pathological T classificationa
pTl
pT2
pT3
pT4
Pathological N classificationa
pN0
pNl
pN2
pN3
Pathological stagea
IlI III
76
29
40
53
6
6
34
49
5
17
55
8
30
12
55
3
47
aPathological TN classification and stage are according to the Japan Lung
Cancer Society classification (1995).
the polymerase chain reaction (PCR) mixture [1O mM Tris-HCI
(pH 8.3), 50 mm potassium chloride, 1.5 mm magnesium chloride,
0.01% gelatin, 0.05% Tween 20, 0.1 mm each dNTPs, 50 pmol of
each sense and antisense primer and 2.5 units of Taq polymerase
(Takara, Kyoto, Japan)] with a total volume of 100 gI. The PCR
and Southern blot hybridization analysis was performed as reported
by Noguchi-Takino et al (1996). Specific primers for the u-PA gene
used in this study were sense 5'-AGAATTCACCACCATCGAGA-
3' and antisense 5'-ATCAGCTTCACAACAGTCAT-3', the target
fragment of which was 474 bp, and the probe oligonucleotide was
5'-AGGCAGATGGTCTGTATAGT-3'. Primers forthe u-PAR gene
were sense 5'-TTACCTCGAATGCATTTCCT-3' and antisense 5'-
TTGCACAGCCTCYTACCATA-3' (PCR product 455 bp), and the
probe was 5'-TCATCAGACATGAGCTGTGA-3'. Primers for the
PAI- 1 gene were sense 5'-ATGGGATTCAAGATTGATGA-3' and
antisense 5'-TCAGTATAGTTGAACTTGTT-3' (PCR product
452 bp) and the probe was 5'-AGAGAGCCAGATTCATCAT-
CAAT-3'. For the PAI-2 gene, sense 5'-TAAGCTGTTTGGTGA-
GAAGT-3', antisense 5'-TACATCATCTGTACAGGTGT-3' (PCR
products 327 bp) and probe 5'-TAGACTTCCTAGAATGTGCA-3'
were used. For the f-actin gene as an internal standard, sense 5'-
TTGAAGGTAGTTlCGTGGAT-3' and antisense 5'-GAAAA-
TCTGGCACCACACCTT-3' (PCR products 592 bp) were used.
Oligonucleotide 5'-ACTGACTACCTCATGAAGAT-3' was used
as the probe. Amplification was performed for 1.5 min at 94°C,
2 min at 48°C and 2 min at 72°C for three cycles, followed by 25
cycles of 40 s at 94°C, 1.5 min at 48°C and 1.3 min at 72°C. The
PCR products were electrophoresed on a 2% agarose gel then
transferred to a nylon membrane filter (Hybond N+, Amersham
International, Buckinghamshire, UK). The transferred products
were hybridized overnight to a 32P-end-labelled probe specific
for the internal sequence of the amplified cDNA fragment
(Southern blotting). The hybridized membrane was subjected to
autoradiography with an X-ray film or scanned with a Fuji BAS
1000 imaging system (Fuji Photo Film, Hamamatsu, Japan) for the
quantitative analysis. The mRNA expression levels of u-PA, u-
PAR, PAI-1 and PAI-2 were standardized with that of 1-actin
mRNA in each sample. The ratio of the relative amount of each
mRNA expression was calculated by the following formula: the
ratio of relative amount = (radioactivity of each PCR product!
radioactivity of PCR product of 3-actin) x 102. In this study, we
defined a tumour as included in the positive-expressing group ifthe
ratio ofrelative amount was higher than 1.0 x 10'.
Immunohistochemical staining
Expressions of u-PA and PAI-2 were assessed by immunohisto-
chemical staining (Nagayama et al, 1994). Paraffin-embedded
tumour tissues were sectioned to a 3-gm thickness, then the
sections were deparaffinized with xylene and dehydrated with
99% ethyl alcohol at 37°C. Endogenous peroxidase was blocked
by treatment with 0.3% hydrogen peroxide in methanol for 20 min
and the specimens were washed with Dulbecco phosphate-
buffered saline (PBS) (pH 7.2) without calcium and magnesium
ions. The sections were incubated with normal goat serum diluted
tenfold with PBS for 15 min at room temperature for the purpose
of blocking the reaction. After being washed with PBS, the
sections were reacted with anti-uPA monoclonal antibody and
anti-PAI-2 monoclonal antibody, which were diluted 50-fold with
PBS containing 1% bovine serum albumin (BSA) for 15 h at 4°C.
Anti-uPA monoclonal antibody (no. 3689) was obtained from
American Diagnostica (Greenwich, CT, USA) and anti-PAI-2
monoclonal antibody (MAI-21) was obtained from Biopool
(Umea, Sweden). After they were washed with PBS, an
avidin-biotin-peroxidase complex was added and the reaction
products were developed by 3,3'-diaminobenzidine (Sigma, St
Louis, MO, USA) with 0.03% hydrogen peroxide. Counterstaining
was conducted with haematoxylin, dehydrated and mounted in a
routine fashion. All reagents except the primary antibody were
used as the negative controls. A routinely processed preparation of
tumourrevealing strong expression ofthe tested antigens served as
a positive control to ensure interassay consistency. Staining was
considered positive when more than 10% of the tumour area was
stained. The immunoreactivities were graded as -, + and ++
according to the staining intensity of the tumour cells: -, none or
less than 10% ofthe positive-staining area; +, 10-50% ofthe posi-
tive-staining area; ++, the strongest staining response (more than
50% at x 200). Immunoreactivities were assessed without knowl-
edge of the mRNA expression level and clinicopathological
findings.
Enzyme-linked immunosorbent assay of PAI-2
In accordance with the method described by Bouchet et al (1994),
levels of PAI-2 antigen were measured in cytosols by an immuno-
enzymatic method with Biopool TintElize (Umea, Sweden). For
extraction, 26 tissue pieces of 250-300 mg wet weight were
pulverized at 4°C in 10 mM Tris-HCl buffer (pH 7.4) containing
1.5 mm EDTA, 0.5 mm dithiothreitol and 10% glycerol. The
suspension was centrifuged (100 000 g at 4°C for 60 min). The
cytosols were collected and stored in liquid nitrogen until use.
Monoclonal anti-PAI-2 antibody recognizes low molecular weight
PAI-2 (44.6 kDa) and glycosylated high molecular weight PAI-2
(60 kDa). After incubation of the cytosols for 2 h at 25°C with
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Figure 1 RT-PCR analysis for u-PA, u-PAR, PAI-1 and PAI-2 in eight surgical specimens of primary lung cancer tissues (T) and adjacent normal lung tissues
(N). The expected sizes (bp) of the RT-PCR products are indicated on the right. Expression of ,B-actin was simultaneously tested as an internal control
agitation, a polyclonal antibody labelled with peroxidase was
added. Absorbance at 405 nm was measured with an Immuno
Reader NJ-2000 (InterMed Japan, Tokyo, Japan). Antigen levels
were obtained from standard curves and protein levels were
assayed using a BCA Protein Assay Kit (Pierce, Rockford, IL,
USA). Results were expressed in ng per mg ofprotein.
Statistics
The X2-test was used for comparison of 2 x 2 tables. The
Mann-Whitney non-parametric test was used to compare node-
positive cases with node-negative cases according to the levels of
PAI-2 mRNA expression. Survival curves were obtained by the
Kaplan-Meier method. The differences in survival period between
the groups were examined by the g-Wilcoxon method. Linear
regression was used for the correlation analysis of quantitative
data. The criterion for statistical significance among the groups
was P < 0.05. The Cox proportional hazard model was used for
multivariate analysis of the overall survival period.
RESULTS
Correlation of mRNA expression of the u-PA system
and clinicopathological findings
To evaluate the relationship between gene expression of the
urokinase system and malignancy of primary lung cancers, we
examined mRNA expression of u-PA, u-PAR, PAI- I and PAI-2 in
105 human lung cancer specimens and eight adjacent normal lung
tissues. In the resected specimens, expression of u-PA, u-PAR and
PAI-1 mRNA was frequently observed. The frequency of mRNA
expression was 84.7% for u-PA, 81.0% for u-PAR and 82.9% for
Table 2 Relationship between nodal metastasis and mRNA expression of
the u-PA system in 105 patients with lung cancer
Lymph node metastasis
(number of patients)
mRNA Positive Negative
u-PA Positive 43 46
Negative 7 9 NSa
u-PAR Positive 43 42
Negative 7 13 NS
PAI-1 Positive 42 45
Negative 8 10 NS
PAI-2 Positive 15 38
Negative 35 17 P < 0.0005
Statistical significance of differences was evaluated by the X2-test, with a
P-value less than 0.05 taken as the criterion of significance. aNS, not
significant.
PAI-1. Furthermore, the expression patterns were similar among
these three factors. In contrast, the frequency of PAI-2 mRNA
expression was lower (51.4%) than that of u-PA, u-PAR and PAI-
1. There were no cases that were negative for u-PA and positive for
PAI-2 expression. The results ofeight cases are shown in Figure 1.
Of the cases without lymph node involvement, case I had low
expression levels of u-PA and related factors. Cases 2, 3 and 4 had
moderate expression levels of u-PA, u-PAR and PAI-1 and cases 2
and 3 had high levels of PAI-2 expression. In cases 5-8 with
lymph node metastasis, mRNA expression of u-PA, u-PAR and
PAI- 1 tended to be at high levels, but PAI-2 expression was dimin-
ished or completely deficient. The relationship between mRNA
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Figure 2 Comparison of the level of PAI-2 mRNA expression of node-
positive cases with that of node-negative cases. The relative amount of PAI-2
mRNA was analysed by the RT-PCR method and standardized to that of
f-actin as an internal control
expression of the u-PA systems and lymph node metastasis was
examined by the x2-test (Table 2). The mRNA expression ofu-PA,
u-PAR and PAI-1 was not related to lymph node metastasis, but
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Figure 3 Kaplan-Meier survival plots for lung cancer patients stratified by
mRNA expression of u-PA and PAI-2. The u-PA (+), PAI-2 (-) group had a
significantly lower survival rate than the other two groups (P < 0.01)
the diminished expression of PAI-2 mRNA was significantly
correlated with lymph node metastasis (P < 0.0005). The expres-
sion levels of PAI-2 mRNA were significantly lower in cases with
lymph node involvement than in cases without lymph node
involvement (Figure 2). Subsequently, the correlation between the
overall survival period of the patients and mRNA expression of
u-PA and PAI-2 was assessed. The median survival period was
84 months in the u-PA-negative group (n = 11), 50 months in the
Figure 4 Staining of u-PA (A, B) and PAI-2 (C, D) using monoclonal antibody in adenocarcinoma of the lung (A, C) and adjacent normal lung tissue (B, D)
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Table 3 Multivariate analysis of clinicopathological findings and mRNA
expression of u-PA and PAI-2 in lung cancer for prognosis
Variable Fvalue P-value
Age: 2 64 vs < 64 years 1.14 0.31 (NS)
pTNM classification
pT 2.89 0.06 (NS)
pN 8.86 0.02
Histology 1.44 0.23 (NS)
mRNA expression
u-PA 6.38 0.01
PAI-2 9.51 < 0.002
NS, not significant.
Table 4 Relationship between nodal metastasis and the expression of u-PA
and PAI-2 antigen
Lymph node metastasis
(number of patients)
Antigen Positive Negative
u-PA Positive 41 41
Negative 9 14 NS
PAI-2 Positive 17 33
Negative 33 22 P < 0.005
Statistical significance of differences was evaluated by the X2-test, with a P-
value less than 0.05 taken as the criterion of significance. NS, not significant.
u-PA-positive plus PAI-2-positive group (ni = 37) and 13 months in
the u-PA-positive plus PAI-2-negative group (n = 25). The 3- and
5-year survival rates in each group were as follows: 72.7% and
60.6% in the u-PA-negative group; 52.3% and 40.9% in the u-PA-
positive-PAI-2-positive group; and 12.0% and 4.0% in the u-PA-
positive-PAI-2-negative group. A significant difference in the
survival period between each group was observed only in the
u-PA-positive-PAI-2-negative group (Figure 3).
A multivariate analysis was performed to compare the prog-
nostic value of u-PA and PAI-2 mRNA expression with that of
other parameters. As presented in Table 3, u-PA and PAI-2 mRNA
expression significantly predicted overall survival in lung cancer
patients and lymph node metastasis was the only other significant
variable.
Immunohistochemical staining of u-PA and PAI-2
The u-PA antigen was detected mainly in the cytoplasm of cancer
cells in 82 (78.1%) of the 105 cases examined. The levels of u-PA
antigen were classified as - in 23 cases, + in 50 cases and ++ in 32
cases. The mean levels of u-PA mRNA expression in the corre-
sponding cases were 7.5 ± 4.8 for the u-PA antigen (-) group,
69.7 ± 39.9 for the (+) group and 81.5 ± 35.8 for the (++) group
respectively. The PAI-2 antigen was also identified mainly in the
cytoplasm of lung cancer cells and localization ofPAI-2 antigen was
similar to that of the u-PA antigen (Figure 4). Positive staining was
observed in 50 cases (47.6%) and the levels of PAI-2 antigen were
classified as - in 55 cases, + in 36 cases and ++ in 14 cases. The mean
expression levels ofPAI-2 mRNA were as follows: (-), 8.0± 5.6; (+),
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Figure 5 Relationship between the level of PAI-2 mRNA expression and
that of PAI-2 antigen expression. The relative amount of PAI-2 mRNA is
analysed by the RT-PCR method and standardized to that of f-actin as an
internal control
75.5 ± 24.1; and (++), 90.7 ± 31.0 respectively. The intensity of
immunostaining coincided with the mRNA expression levels ofu-PA
and PAI-2. The relationship between the expression ofu-PA and PAI-
2 antigen and lymph node metastasis was examined by the x2-test.
The results are presented in Table 4. Positive expression of u-PA
antigen was not related to lymph node metastasis, but negative
expression of PAI-2 antigen was significantly correlated with lymph
node metastasis (P < 0.005).
ELISA of PAI-2
We examined the PAI-2 antigen level in 26 cases by ELISA tech-
nique to evaluate the relationship with that of PAI-2 mRNA
expression. As shown in Figure 5, the PAI-2 antigen level was
significantly correlated with the expression level of PAI-2 mRNA
in 26 cases (r = 0.84).
DISCUSSION
Tumour cell invasion and metastasis formation are multifactorial
processes. Degradation of the extracellular matrix during tumour
invasion requires the coordinated action of cell-secreted proteo-
lytic enzymes and their inhibitors. u-PA is one of these proteolytic
enzymes, and the elevated levels of u-PA have been implicated in
these invasive processes (Dan0 et al, 1985; Ossowski, 1988; Testa
and Quigley, 1990; Pollanen et al, 1991; Del Vecchio et al, 1993).
u-PA is inactivated by several inhibitors such as PAI-1, PAI-2,
PAI-3 and protease nexin 1 (Pollanen et al, 1991). It has been
reported that overexpression ofu-PA, its specific receptor (u-PAR)
and PAI- 1 was correlated with the clinicopathological findings in
malignant tumours, including lung and colon cancer (Dan0 et al,
1985; Ganesh et al, 1994). However, there is little information
about the physiological significance of PAI-2 in the microenviron-
ment of cancer cells. We examined the expression of u-PA and its
related factors in 105 surgically resected lung cancer tissues, with
a view to clinical use.
The mRNA expression levels of u-PA and related factors were
much higher in cancerous tissues than in adjacent normal lung
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tissues. In our immunohistochemical study, the staining of u-PA
and PAI-2 was markedly stronger in lung cancer cells than in the
surrounding cells. Nagayama et al (1994) have also reported that
u-PA, PAI-I and PAI-2 antigen levels are significantly higher than
in normal lung tissue, suggesting that u-PA and related factors in
lung cancer tissue are derived mainly from cancer cells.
The mRNA expression of u-PA was observed frequently in
human lung cancer tissues. Also, mRNA expression of u-PA was
often accompanied by that of u-PAR and PAI-1. Many researchers
have reported that the expression of u-PA frequently occurs
concomitantly with that of u-PAR and PAl-I in various tumours
(Dan0 et al, 1985; Testa and Quigley, 1990; Polainen et al, 1991;
Ishikawa et al, 1996). The activity of specific receptor binding
with u-PA is considered to be important for cancer cells in the
activation of single-chain u-PA to two-chain u-PA, localizing and
enhancing proteolytic activity on the surface ofcancer cells (Veale
et al, 1990; Cohen et al, 1991; Ellis and Dan0, 1991; Hollas and
Boyd, 1991; Pyke et al, 1991; Olson et al, 1992). This activity is
probably important in the formation of lymph node metastasis
(Del Vecchio et al, 1993; Carriero et al, 1994).
However, synchronized expression of u-PA and PAI-I is not
consistent with the assumption that u-PA is a critical factor for
tumour cell invasion. PAI-1 is able to inhibit u-PA activity and
tumour cell invasion in an in vitro system (Nielsen et al, 1986;
Cajot et al, 1990; Cubellis et al, 1990), but the practical action of
PAI-I in vivo, especially in cancer cell invasion and metastasis,
has remained obscure. Bouchet et al (1994) confirmed the poor
prognosis of breast cancer patients whose tumours contained a
large amount of PAl-1. In their report, they mentioned that PAI-I
does not appear to play a role as a u-PA inhibitor. Further exami-
nation is required to clarify the physiological significance of PAT-
1 in the regulation of u-PA activity in vivo.
In this study, the depressed expression ofPAI-2 mRNA and PAl-
2 antigen was significantly correlated with lymph node metastasis.
Furthermore, in the u-PA-positive cases, the survival rate of
patients with negative mRNA expression of PAI-2 was signifi-
cantly worse than that of patients with positive mRNA expression
of PAI-2 in lung cancers. These results support the findings that
depressed PAI-2 antigen detected by the immunoenzymic method
is correlated with a shortened disease-free survival in breast cancer
(Foekens et al, 1995; Duggan et al, 1997) and that the occurrence of
lymph node metastasis follows diminished expression of PAI-2 in
breast cancer (Ishikawa et al, 1996), non-small-cell lung cancer
(Nagayama et al, 1994) and colon cancer (Naitoh et al, 1995). Our
previous and present findings and the reports of others suggest that
PAI-2 is a more important inhibitor of u-PA activity than PAI-1.
Several reports have shown that the activity of receptor-bound u-
PA is inhibited by PAI-2 in human cancer cells and human mono-
cyte (Kirchheimer et al, 1989; Baker et al, 1990; Pollanen et al,
1990). Our current study suggests that PAI-2 is deeply involved in
tumour growth and tissue degradation. This notion is also
supported by other experiments in which transfection of recombi-
nant PAI-2 cDNA to HT-1080 cells or Met 24 cells effectively
depressed their metastatic ability (Laug et al, 1993; Mueller et al,
1995). The regulating mechanism ofPAI-2 expression still remains
unclear. Heuvel et al (1994) have reported that dioxin induces
mRNA expression of PAI-2. Recently, some reports have shown
that tumour necrosis factor and phorbor esters induce gene expres-
sion of PAI-2 (Anthony et al, 1996; Maurer and Medcalf, 1996).
There are no reports on the factors that suppress PAI-2 expression.
Possibly, the factors or systems which negatively regulate PAI-2
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expression may exist in the cancer cell itself or in the micro-
environment surrounding the cancer tissue. It will be necessary to
clarify the system ofregulating PAI-2 expression in order to obtain
novel insights to regulate tumour invasion and metastasis.
In conclusion, uPA and related factors may be key molecules for
the extracellular matrix degradation enzyme. Furthermore, PAI-2
is useful as a marker of prognosis or the target molecule for
preventing cancer metastasis.
ACKNOWLEDGEMENTS
This work was supported in part by a Grant-in-Aid for Cancer
Research and the 2nd-Term Comprehensive Ten-Year Strategy for
Cancer Control from the Ministry of Health and Welfare, and also
a Grant-in-Aid for Scientific Research on Priority Areas from the
Ministry of Education, Sciences, Sports and Culture, Japan.
REFERENCES
Anthony ED. Shen Y, Ruegg M and Medcalf RL (1996) Molecular mechaniisms
governing tumour-necrosis-factor-mediated regulation ofplasminogen-
activator inhibitor type-2 gene expression. Eur] J Biochemn 241: 93-1))))
Baker MS. Bleakley P, Woodrow GC and Doe F (1990) Inhibition of cancer cell
urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent
effects on extracellular matrix degradation. Cncrer Res 50: 4676-4684
Blasi F. Stoppeli MP and Cubellis MV (1986) The receptor for urokinase-
plasminogen activator. J Cell Bioc/hern 32: 179-186
Bouchet C, Spyratos F, Martin PM. Hacene K. Gentile A and Oglobine J (1994)
Prognostic value of plasminogen activator (uPA) and plasminogen activator
inhibitors PAI-I and PAI-2 in breast carcinomas. B] J Concer 69: 398-405
Cajot JF. Bamat J. Bergomelli GE. Kruithof EK. Medcalf RL. Testuz J and Sordat B
(1990)) Plasminogen-activator inhibitor type I is a potent inhibitor of-
extracellular matrix degradation by fibrosarcoma and colon carcinomlia cells.
Pr-oc Noitd Acd Sci USA 87: 6936-6943
Carriero MV. Frainco P. Del Vecchio S, Massa 0. Botti G. D'Aiuto G, Stoppelli MP
and Salvatore M ( 1994) Tissue distribution of soluble and receptor-bound
urokinase in human breast cancer using a panel of monoclonal antibodies.
Concer Rex 54: 5445-5454
Cohen RL, Xi XP, Crewley CW, Lucas BK, Levinson AD and Schum-an MA (1991)
Effects of urokinase receptor occupancy on plasmin generation and proteolysis
of basement membrane by human tumor cells. Blood 78: 479-487
Conboy JG. Chanl J, Mohandas N and Kan YW (1988) Multiple protein 4.1 isoforms
produced by alternative splicing in human erythroid cells. PrYoc NoitlAcod Sci
USA 85: 90)62-9065
Cubellis MV, Wun TC and Blasi F (1990)) Receptor-mediated internalization and
degradation of urokinase is caused by its specific inhibitor PAI- 1. EMBO J 9:
10)79-1085
Dan0 K. Andreason PA. Gr0ndahl-Hansen J. Kr-istensen P, Nielsen LS and Skriver L
(1985) Plasminogen activators, tissue degradation, and cancer. Ade Concere Res
44: 139-266
Del Vecchio S, Stoppelli MP, Carriero MV. Fonti R, Massa 0. Li PY, Botti G, Cerra
M, D'Aiuto G, Esposito G and Salvatore M (1993) Human urokinase receptor
concentration in malignant and benign breast tumors by in vitro quantitative
autoradiography: comparison with urokinase levels. Coniicer- Rex 53: 3198-3206
Duggan C, Kennedy S, Kramer MD, Barnes C, Elvin P, McDermott E, O'Higgins N
and Duffy MJ ( 1997) Plasminogen activator inhibitor type 2 in breast cancer.
Br] J Cance- 76: 622-627
Ellis V and Dano K (1991) Plasminogen activation by receptor-bound urokinase.
Serniii Thromnb Henixost 17: 194-200
Foekens JA, Buessecker F. Peters HA, Krainick U, Puttenl WLJ. Look MP, Klijn
JGM and Kramner MD (1995) Plasminogen activator inhibitor-2: prognostic
relevance in 1012 patients with primary breast cancer. Cinc-erRex 55:
1423-1427
Ganesh S, Sier CFM, Griffioen G, Vloedgraven HJM, de Boer A, Welvaart K, van
de Velde CJH, van Krieken JHJM, Verheijen JH, Lamers CBHW and Verspaget
HW (1994) Prognostic relevance ofplasminogen activators and their inhibitors
in colorectal cancer. Cancer Res 54: 4065-4071
Goldfarb RH, MuLrano G. Brundage R, Siegal GP, Terranova V, Galrbisa S and Liotta
LA (1986) Degradation ofglycoprotein and collagenous comiiponents of the
C) Cancer Research Campaign 1998Expression ofPAI-2 mRNA in lung cancer 839
basement membrane, studies with urokinase-type plasminogen activator, alfa-
thrombin and plasmin. Tltrootb Hentostaisis 12: 335-336
Heuvel JPV, Clark GC, Kohn MC. Tritscher AM, Greenlee WF, Lucier GW and Bell
DA (1994) Dioxin-responsive genes, examination ofdose-response
relationships using quantitative reverse transcriptase-polymerase chain
reaction. Caticer Res 54: 62-68
Hollas W and Boyd D (1991) Urokinase-dependent proteolysis in cultured colon
cancer is directed by its receptor. Semniui Thromib Hemtiost 17: 225-230
Ishikawa N, Endo Y and Sasaki T (1996) Inverse correlation between mRNA
expression of plasminogen activator inhibitor-2 and lymph node metastasis in
human breast cancer. JpIt J Cantice- Res 87: 480-487
Kirchheimer JC and Remold HG (1989) Functional characteristics of receptor-bound
urokinase on human monocytes, catalytic efficiency and susceptibility to
inactivation by plasminogen activation inhibitors. Blood 74: 1396-1402
Laug WE, Cao XR, Yu YB. Shimada H and Kruithof EKO (1993) Inhibition of
invasion of HT1080 sarcoma cells expressing recombinant plasminogen
activator inhibitor 2. Ctotnce Res 53: 6051-6057
Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V and Garbisa S (1981)
Effect ofplasminogen activator (urokinase), plasmin. and thrombin on
glycoprotein and collagenous components of basement membrane. Cancer Res
41: 4629-4636
Maurer F and Medcalf RL ( 1996) Plasminogen activator inhibitor type 2 gene
induction by tumor necrosis factor and phorbol ester involves transcriptional
and post-transcriptional events, identification of a functional nonameric AU-
rich motif in the 3'-untranslated region. JBiol C/ein 271: 26074-26080
Mueller BM, Yu YB and Laug WE (1995) Overexpression ofplasminogen activator
inhibitor 2 in human melanomna cells inhibits spontaneous metastasis in
scid/scid mice. Proc Naitl Acad Sci USA 92: 205-209
Nagayama M, Sato A, Hayakawa H, Urano T, Takada Y and Takada A (1994)
Plasminogen activators and their inhibitors in non-small cell lung cancer, low
content of type 2 plasminogen activator inhibitor associated with tumor
dissemination. Cancer 73: 1398-1405
Naitoh H, Eguchi Y, Ueyama H, Kodama M and Hattori T (1995) Localization of
urokinase-type plasminogen activator inhibitor- 1,2 and plasminogen in colon
cancer. Jpn J Cacetr Res 86: 48-56
@) Cancer Research Campaign 1998
Nielsen LS. Andreasen PA, Gr0ndahl-Hansen J, Skriver L and Dan0 K (1986)
Plasminogen activators catalyze conversion of inhibitor from fibrosarcoma
cells to an inactive form with a lower apparent molecular mass. FEBS Lett 196:
269-273
Noguchi-Takino M, Endo Y, Yonemura Y and Sasaki T (1996) Relationship between
expression ofplasminogen activator system and metastatic ability in human
cancers. hit J Onicol 8: 97-105
Olson D, Po1linen J, Hoyer-Hansen G, Ronne E, Sakaguchi K and Wun TC (1992)
Intemalization of the urokinase-plasminogen activator inhibitor type-I complex
is mediated by the urokinase receptor. J Biol Chem 267: 9129-9133
Ossowski L (1988) In vivo invasion of modified chorioallantoic membrane by tumor
cells: the role ofcell surface-bound urokinase. J Cell Biol 107: 2437-2445
Pollanen J, Vaheri A, Tapiovaara H, Riley E, Bertram K and Woodrew G (1990)
Pro-urokinase activation on the surface ofhuman rhabdomyosarcoma cells,
localization and inactivation of newly formed urokinase-type plasminogen
activator by recombinant class 2 plasminogen activator inhibitor. Proc Natl
Acad Sci USA 87: 2230-2234
Pollnen J, Stephenes RW and Vaheri A (1991) Directed plasminogen activation at
the surface of normal and malignant cells. Adi' Canlcer Res 57: 273-328
Pyke C, Kristensen P, Ralfkiaer E, Grondahl-Hansen J and Brasi F (1991)
Urokinase-type plasminogen activator is expressed in stromal cells and its
receptor in cancer cells at invasion foci in human colon adenocarcinomas.
Ain J Pathol 138: 1059-1067
Robbins KC, Summaria L, Hsieh B and Shah RJ (1967) The peptide chains of
human plasmin, mechanism of activation system of human plasminogen to
plasmin. J Biol Chem 242: 2333-2342
Salo T. Liotta LA. Keski-Oja J, Turpeenniem-Hujanen T and Tryggvason K (1982)
Secretion ofbasement membrane collagen degrading enzyme and plasminogen
activator by transformed cells - role in metastasis. IJut J C(ancer 30: 669-673
Testa JE and Quigley JP (1990) The role of urokinase-type plasminogen activator in
aggressive tumor cell behavior. Cci'acer Metastasis Rer 9: 353-367
The Japan Lung Cancer Society ( 1995) General Riulesfor Clinical and Pathological
Records( ofLuntig Canicer. 4th edn. Kanehara: Tokyo
Veale D, Needham G and Harris AL (1990) Urokinase receptors in lung cancer and
normal lung. Aniticanzcer Res 10: 417-422
British Journal of Cancer (1998) 78(6), 833-839